Plasmid DNA is circular DNA molecules that can replicate independently of chromosomal DNA inside living cells. They are used to deliver therapeutic genes into target cells for diseases like cancer and infectious diseases. Plasmid DNA products are important components of gene and cell therapies. The growing adoption of gene therapy and cell therapy to treat various conditions like cancer, cardiac disorders is driving the demand for plasmid DNA which is used in research, drug discovery and therapeutic development.
The global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing demand for gene and cell therapies is one of the major trends propelling the growth of the plasmid DNA manufacturing market. Gene therapy uses genes to treat or prevent disease, while cell therapy uses human cells to replace or repair damaged cells. Both therapies have shown promising results for various conditions like cancer, cardiovascular disease, infectious diseases etc. With over 2000 active cell and gene therapy clinical trials ongoing worldwide, the need for high quality plasmid DNA for research and development of these advanced therapies is surging. This rising interest in gene and cell therapies from pharmaceutical and biotech companies is expected to drive the plasmid DNA manufacturing market during the forecast period.
SWOT Analysis
Strength: Plasmid DNA manufacturing is witnessing increasing adoption in target diseases areas like oncology, infectious diseases and genetic & rare diseases. This presents a large market opportunity.
Weakness: Challenges around developing standardized and scalable manufacturing processes, developing robust quality systems and ensuring product purity and stability.
Opportunity: Growing interest in gene & cell therapies has boosted R&D activity and clinical trials involving plasmid DNA. Emerging applications in DNA vaccines also present opportunities.
Threats: Intense competition from existing and new market players. Stringent regulatory requirements around plasmid safety, efficacy and quality can delay product development and market entry.
Key Takeaways
The global Plasmid DNA Manufacturing Market is expected to witness high growth over the forecast period of 2023 to 2030. Global Plasmid DNA Manufacturing Market Size for 2023 is estimated to be US$ 901.2 Billion with a projected CAGR of 4.8% during the forecast period.
Regional analysis comprises: North America is currently the dominant and fastest growing regional market for Plasmid DNA manufacturing due to high ongoing R&D activity and clinical trials in cell and gene therapies. Asia Pacific is also expected to register high growth owing to increasing biopharmaceutical manufacturing activity in countries like China and India.
Key players related content: Key players operating in the Plasmid DNA manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing. Major players are focusing on developing advanced manufacturing capabilities to produce high quality plasmid DNA at commercial scale to meet the growing demand.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it